Impact of Various Diets on Surgical Complications

NCT05069402 — Not applicable, Completed, 300 participants, Stanley Dudrick's Memorial Hospital

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Impact of Immunomodulating Oral Nutrition on Surgical Complications

RegistryNCT05069402, acronym IMM4
StatusCompleted
PhaseNot applicable
Study typeInterventional; randomized, parallel, masking: triple, treatment
Enrollment300 (Actual)
SponsorStanley Dudrick's Memorial Hospital (Other)
ConditionsComplication,Postoperative
InterventionsImmunonutrition, High-protein, Standard ONS (Dietary supplement)
Datesstart 2021-09-01, primary completion 2025-12-31, completion 2025-12-31, first posted 2021-10-06, last updated 2026-01-13
Locations2 sites in Poland

Related Papers Related Patents Related Grants Related Experts
All trials for Complication,Postoperative All trials of Immunonutrition All trials of High-protein

-Summary

The optimalisation of the health status of patients scheduled for major surgery has been considered to be the most important point of perioperative care, and nutritional intervention has been perceived a key point of that intervention. Immunomodulating diets were thought to reduce cmplications, hoever recent studies put that opnion in doubt. This study was designed to assess the actual clinical significance of oral immunonutrition.

Expand all sections  ·  Collapse all

+Detailed description

The optimalisation of the health status of patients scheduled for major surgery has been considered to be the most important point of perioperative care, and nutritional intervention has been perceived a key point of that intervention. Italian studies followed by metanalyses demonstrated the superiority of immunomodulating diets (IM) over any other preoperative nutrition, hence the surgical guidelines for enteral nutrition published by European Society for Clinical Nutrition and Metabolism (ESPEN) in 2006 recommended to use IM for 7-14 days preoperatively in all patients undergoing major surgeries. Some authors questioned IM by showing no benefit of IM over standard enteral nutrition. Other authors observed similar results.The debate was far from being over - in 2015 a new metanalysis stated that perioperative enteral nutrition is the best option for managing clinical status of patients who underwent selective surgery for gastrointestinal cancer. One year later, ESPEN changed its surgical recommendations and advised to use IM preoperatively in malnourished and perioperatively in well-nourished patients. American recommendations remained unchanged and, according to them, it is advised to use IM preoperatively in all surgical patients, however, high-protein nutrition could also be an beneficial option.

To address those doubts and to assess the actual clinical significance of oral immunonutrition, a randomized, two center, prospective clinical trial was conducted.

+Arms and interventions

ArmTypeInterventionsDescription
ImmunonutritionExperimentalDietary Supplement: ImmunonutritionOral immunonutrition containing arginine, omega-PUFAs and antioxidants
High-protein dietActive comparatorDietary Supplement: High-proteinOral nutrition with high-protein content
Standard nutritionActive comparatorDietary Supplement: Standard ONSOral nutrition with standard components
  • Immunonutrition (Dietary supplement): diet with immunonutrients
  • High-protein (Dietary supplement): Oral nutrition with high-protein content
  • Standard ONS (Dietary supplement): Oral nutrition with standard ingredients

+Outcome measures

Primary outcomes

  • Surgical complications [6 months]: Number and type of surgical complications
  • Infectious complications [6 months]: Number and type of infectious complications

Secondary outcomes

  • Length of stay [6 months]: Days of hospital stay after the operation

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* no sign of malnutrition (defined as one of the following unintentional weight loss by at least 10% or body mass index (BMI) < 18),
* good general status (Karnofsky Performance Index > 80,
* Eastern Cooperative Oncology Group (ECOG) grade 0 or 1);
* no confirmed neoplastic dissemination no severe concomitant disease (heart, lung, kidney, liver failure, chronic obstructive pulmonary disease \[COPD\], coronary aortic bypass graft \[CABG\], etc.),
* no history of known allergies or drug intolerance to analyzed substances.

Exclusion Criteria:

* Patients malnourished or with metastatic disease,
* pregnant,
* in poor general status (Karnofsky <80, Eastern Cooperative Oncology Group (ECOG) > 1),
* recent history of severe heart, lung, kidney or liver failure,
* history of allergies or drug intolerance

+Locations (2)

FacilityCityCountryStatus
Narodowy Instytut OnkologiiKrakow, MalopolskaPoland
Stanley Dudrick's Memorial HospitalSkawina, MalopolskaPoland

+Investigators